Aspirin's long-standing role in atherosclerotic cardiovascular disease (ASCVD) is narrowing, and shorter courses of dual antiplatelet therapy (DAPT) followed by P2Y12 inhibitor monotherapy offer a bleeding-sparing option for selected patients after percutaneous coronary intervention (PCI), according to a new scientific statement from the American College of Cardiology (ACC).